Takeda Pharmaceutical Company Limited
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 2 | ×1.50 | 3 |
Strategy profile
Based on 10 disclosed transactions, Takeda Pharmaceutical Company Limited concentrates its licensing activity in Hematology, Neurology, and Oncology. Takeda Pharmaceutical Company Limited pays a 1.50x premium over market median. Their most common deal structure is License, with an average disclosed value of $1.2B. Most recent activity: 2024.
Pipeline coverage & gaps
Takeda Pharmaceutical Company Limited has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 7 | $180M | $802M |
| Collaboration | 2 | $173M | $2.1B |
| Option | 1 | $100M | $2.2B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2024 | Elritercept (KER-050) | Keros Therapeutics, Inc. | anemia associated with lower-risk myelodysplastic syndromes (MDS) and myelofibrosis | phase_2 | $200M | $1.3B |
| 2024 | Elritercept (KER-047) | Keros Therapeutics | anemia in MDS and myelofibrosis | phase_2 | $200M | $1.3B |
| 2024 | ACI-24.060 | AC Immune SA | alzheimers_disease | phase_2 | $100M | $2.2B |
| 2024 | Rusfertide | Protagonist Therapeutics | polycythemia vera | phase_3 | $300M | $630M |
| 2023 | PIKFYVE program (AS-202) | AcuraStem | ALS | preclinical | — | $580M |
| 2023 | ELAHERE | ImmunoGen | platinum-resistant ovarian cancer | approved | $23M | $158M |
| 2023 | Fruquintinib | HUTCHMED Limited | colorectal cancer | phase_3 | $400M | $1.1B |
| 2021 | P-FVIII-101 | Poseida Therapeutics | Hemophilia A | preclinical | $45M | $3.6B |
| 2021 | Soticlestat (TAK-935/OV935) | Ovid Therapeutics | Dravet syndrome and Lennox-Gastaut syndrome | phase_2 | $196M | $856M |
| 2010 | Feraheme | AMAG Pharmaceuticals, Inc. | iron deficiency anemia | approved | $60M | $280M |
How this is computed
For each Takeda Pharmaceutical Company Limited deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 4 disclosed deal premiums vs. peer medians. Raw premium 1.807, clamped to [0.7, 1.5].